HC Wainwright Predicts Valneva’s Q3 Earnings (NASDAQ:VALN)

Valneva SE Sponsored ADR (NASDAQ:VALN) – Equities researchers at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Valneva in a research note issued to investors on Friday, August 14th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their prior estimate of ($0.21). The consensus estimate for Valneva’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Valneva’s Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at $1.80 EPS, FY2028 earnings at $2.12 EPS, FY2029 earnings at $2.26 EPS and FY2030 earnings at $3.94 EPS.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%.The business had revenue of $39.37 million for the quarter, compared to analyst estimates of $44.17 million.

Other equities research analysts have also issued reports about the stock. Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a research note on Wednesday, April 22nd. TD Cowen began coverage on shares of Valneva in a report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Four research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.98.

Valneva Stock Performance

Valneva stock opened at $7.06 on Tuesday. The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The stock has a market cap of $669.92 million, a PE ratio of -3.35 and a beta of 1.77. Valneva has a 12-month low of $4.75 and a 12-month high of $12.25. The business’s 50-day moving average price is $5.28 and its two-hundred day moving average price is $6.89.

Institutional Investors Weigh In On Valneva

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new position in Valneva during the third quarter valued at about $124,000. XTX Topco Ltd bought a new stake in Valneva in the fourth quarter worth about $94,000. Marex Group plc purchased a new stake in shares of Valneva during the 2nd quarter worth approximately $64,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva in the 4th quarter worth approximately $44,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.